Xbrane Biopharma AB (publ)





Market price today

  • -0.1290

    P/E Ratio

  • 0.0106

    PEG Ratio

  • 304.07M

    MRK Cap

  • 0.00%

    DIV Yield

Xbrane Biopharma AB (publ) (XBRANE-ST) Stock Price & Analysis

Shares Outstanding


Gross Profit Margin


Operating Profit Margin


Net Profit Margin


Return on Assets


Return on Equity


Return on Capital Employed


Company general description and statistics

Sector: Healthcare
Industry: Biotechnology
CEO:Mr. Martin Amark
Full-time employees:93
Address:Retzius väg 8

Xbrane Biopharma AB (publ), a biotechnology company, develops, manufactures, and sells biosimilars. The company is developing Xlucane, a ranibizumab biosimilar that is in Phase III clinical trials used for the treatment of wet age-related macular degeneration, diabetic macular edema, diabetic related retinopathy, and retinal vein occlusion. Its pre-clinical phase products include Xcimzane for rheumatoid arthritis, axial spondylarthrosis, psoriatic arthritis, and psoriasis and crohn diseases; Xoncane for acute lymphocytic leukemia; Spherotide for prostate cancer, breast cancer, endometriosis, and myoma; and Xdivane for melanoma, lung, head and throat, bladder, and urinary tract cancer, as well as for renal cell carcinoma. The company has a strategic biosimilar development partnership with STADA Arzneimittel AG to evaluate development and commercialization collaborations around its Xcimzane and Xdivane preclinical biosimilars. Xbrane Biopharma AB (publ) was founded in 2008 and is headquartered in Solna, Sweden.

General Outlook

When we look at how much money they make before expenses, they keep 0.147% as profit. This shows they're good at controlling costs and are financially stable. Their operating profit, which is money made from regular business activities, is -1.336%. This means they run their business efficiently. Lastly, after paying all their bills, they still have a profit of -1.626%. This tells us they're good at keeping money after all costs.

Return on Investments

The company's asset efficiency, represented by a robust -0.594% return, is a testament to Xbrane Biopharma AB (publ)'s adeptness in optimizing resource deployment. Xbrane Biopharma AB (publ)'s utilization of its assets to generate profits is strikingly evident through a noteworthy return on equity of -1.223%. Furthermore, the proficiency of Xbrane Biopharma AB (publ) in capital utilization is underscored by a remarkable -0.975% return on capital employed.

Liquidity Ratios

Analyzing XBRANE.ST liquidity ratios reveals its financial health of the firm. The current ratio of 141.38% gauges short-term asset coverage for liabilities. The quick ratio (41.82%) assesses immediate liquidity, while the cash ratio (20.03%) indicates cash reserves.

Current Ratio141.38%
Quick Ratio41.82%
Cash Ratio20.03%

Profitability Ratios

XBRANE.ST profitability indicators offer a lens into its earnings landscape. A pretax profit margin of -134.92% underscores its earnings before tax deductions. The effective tax rate stands at -20.53%, revealing its tax efficiency. The net income per EBT, 120.53%, and the EBT per EBIT, 100.99%, provide insights into its earnings hierarchy. Lastly, with an EBIT per revenue ratio of -133.60%, we grasp its operational profitability.

Pretax Profit Margin-134.92%
Effective Tax Rate-20.53%
Net Income per EBT120.53%
EBT per EBIT100.99%
EBIT per Revenue-133.60%

Operational Efficiency

Operational metrics shed light on its business agility. With an operating cycle of 1.41, it details the span from stock purchase to revenue.

Days of Sales Outstanding42
Days of Inventory Outstanding192
Operating Cycle300.40
Days of Payables Outstanding56
Cash Conversion Cycle245
Receivables Turnover3.35
Payables Turnover6.57
Inventory Turnover1.91
Fixed Asset Turnover2.71
Asset Turnover0.37

Cash Flow Ratios

Peering into the cash flow metrics reveals liquidity and operational efficiency. The operating cash flow per share, -1.54, and free cash flow per share, -1.61, depict cash generation on a per-share basis. The cash per share value, 0.25, showcases liquidity position. Lastly, the operating cash flow sales ratio, -1.70, offers insight into cash flow relative to sales.

Operating Cash Flow per Share-1.54
Free Cash Flow per Share-1.61
Cash per Share0.25
Operating Cash Flow Sales Ratio-1.70
Free Cash Flow to Operating Cash Flow Ratio1.04
Cash Flow Coverage Ratio-2.15
Short Term Coverage Ratio-5.34
Capital Expenditure Coverage Ratio-22.31
Dividend Paid and Capex Coverage Ratio-22.31

Debt and Leverage Ratios

Diving into debt and leverage metrics unveils the company's financial structure. The debt ratio, at 28.89%, highlights its total liabilities relative to assets. With a debt-equity ratio of 1.10, we discern the balance between debt and equity financing. The long-term debt to capitalization, 39.72%, and total debt to capitalization, 52.42%, ratios shed light on its capital structure. An interest coverage of -36.82 indicates its ability to manage interest expenses.

Debt Ratio28.89%
Debt Equity Ratio1.10
Long Term Debt to Capitalization39.72%
Total Debt to Capitalization52.42%
Interest Coverage-36.82
Cash Flow to Debt Ratio-2.15
Company Equity Multiplier3.81

Per Share Data

Speaking about the per share data offers a perceptive view of financial distribution. The revenue per share, 0.94, provides a glimpse into top-line earnings distributed across each share. Net income per share, -1.53, reflects the portion of profit attributed to each share. The book value per share, 0.68, represents the net asset value distributed per share, while the tangible book value per share, 0.28, excludes intangible assets.

Revenue Per Share0.94
Net Income Per Share-1.53
Book Value Per Share0.68
Tangible Book Value Per Share0.28
Shareholders Equity Per Share0.68
Interest Debt Per Share0.82
Capex Per Share-0.07

Growth Ratios

Delving into growth metrics provides a snapshot of financial expansion. The revenue growth rate, 314.33%, indicates top-line expansion, while the gross profit growth, -66.00%, reveals profitability trends. EBIT growth, -86.76%, and operating income growth, -86.76%, offer insights into operational profitability progression. The net income growth, -125.39%, showcases bottom-line expansion, and the EPS growth, -101.32%, measures the growth in earnings per share.

Revenue Growth314.33%
Gross Profit Growth-66.00%
EBIT Growth-86.76%
Operating Income Growth-86.76%
Net Income Growth-125.39%
EPS Growth-101.32%
EPS Diluted Growth-101.32%
Weighted Average Shares Growth12.26%
Weighted Average Shares Diluted Growth12.26%
Operating Cash Flow Growth-109.72%
Free Cash Flow Growth-66.68%
10-Year Revenue Growth per Share1070.31%
5-Year Revenue Growth per Share-94.53%
3-Year Revenue Growth per Share2108.46%
10-Year Operating CF Growth per Share-71.95%
5-Year Operating CF Growth per Share-122.54%
3-Year Operating CF Growth per Share-7.64%
10-Year Net Income Growth per Share-71.15%
5-Year Net Income Growth per Share24.09%
3-Year Net Income Growth per Share-8.00%
10-Year Shareholders Equity Growth per Share-81.68%
5-Year Shareholders Equity Growth per Share-94.66%
3-Year Shareholders Equity Growth per Share-58.05%
Receivables Growth49.99%
Inventory Growth112.61%
Asset Growth-5.36%
Book Value per Share Growth-64.08%
Debt Growth505.65%
R&D Expense Growth53.16%
SGA Expenses Growth-41.03%

Other Metrics

Venturing into other key metrics unveils diverse facets of financial performance. The enterprise value, 2,698,172,280, captures the company's total value, considering both debt and equity. Income quality, 1.26, assesses the reliability of reported earnings. The sales, general, and administrative to revenue ratio, 0.17, gauges operational efficiency, while the research and development to revenue, 128.09%, highlights investment in innovation. The ratio of intangibles to total assets, 15.25%, indicates the value of non-physical assets, and capex to operating cash flow, 4.12%, measures reinvestment capability.

Enterprise Value2,698,172,280
Income Quality1.26
Sales General and Administrative to Revenue0.17
Research and Development to Revenue128.09%
Intangibles to Total Assets15.25%
Capex to Operating Cash Flow4.12%
Capex to Revenue-7.02%
Capex to Depreciation-78.24%
Stock-Based Compensation to Revenue0.77%
Graham Number4.83
Return on Tangible Assets-70.09%
Graham Net Net-1.22
Working Capital135,136,000
Tangible Asset Value71,665,000
Net Current Asset Value-20,480,000
Invested Capital1
Average Receivables59,317,000
Average Payables27,135,500
Average Inventory78,558,000
Days Sales Outstanding109
Days Payables Outstanding50
Days of Inventory On Hand174

Valuation Ratios

Exploring the valuation ratios offers insights into perceived market value. The price to book value ratio, 0.29, and the price to book ratio, 0.29, reflect the market's valuation relative to the company's book value. The price to sales ratio, 1.27, provides a perspective on valuation in relation to sales. Ratios like price to free cash flows, -0.72, and price to operating cash flows, -0.12, gauge market valuation against cash flow metrics.

Price Book Value Ratio0.29
Price to Book Ratio0.29
Price to Sales Ratio1.27
Price Cash Flow Ratio-0.12
Price Earnings to Growth Ratio0.01
Enterprise Value Multiple-0.46
Price Fair Value0.29
Price to Operating Cash Flow Ratio-0.12
Price to Free Cash Flows Ratio-0.72
Price to Tangible Book Ratio14.78
Enterprise Value to Sales11.30
Enterprise Value Over EBITDA-9.34
EV to Operating Cash Flow-6.63
Earnings Yield-15.33%
Free Cash Flow Yield-16.72%
Trusted project
“All information displayed on the site is verified. High quality project and financial performance”
Eugene Alexeev
NumFin Founder and investing enthusiast

Frequently Asked Question

How many company shares are outstanding in 2024?

There are stock number shares outstanding of Xbrane Biopharma AB (publ) (XBRANE.ST) on the STO in 2024.

What is P/E ratio of enterprise in 2024?

The current P/E ratio of enterprise is -0.129 in 2024.

What is the ticker symbol of Xbrane Biopharma AB (publ) stock?

The ticker symbol of Xbrane Biopharma AB (publ) stock is XBRANE.ST.

What is company IPO date?

IPO date of Xbrane Biopharma AB (publ) is 2016-02-03.

What is company current share price?

Current share price is 0.190 SEK.

What is stock market cap today?

The market cap of stock today is 304065727.000.

What is PEG ratio in 2024?

The current 0.011 is 0.011 in 2024.

What is the number of employees in 2024?

In 2024 the company has 93.